Study of a Combination of Drugs on Newly Diagnosed Brain Tumor

What we are studying

The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib to see if veliparib combined with temozolomide has an effect in your particular type of brain tumor. Study participants will be randomized to receive veliparib or placebo with temozolomide.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Newly diagnosed

What is involved

  • Study participants will receive temozolomide (TMZ) and veliparib/placebo for 6 cycles (just under 6 months)

Compensation

None

Contact Information

Study Coordinator
Michele Harmon
Email
mharmon@wakehealth.edu
Phone
336-713-6925

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.